BACTI_B: License-driven growth and proven infection prevention technology fuel strong financial momentum

About this update from Bactiguard Holding Ab

Strong growth in license revenues and partnerships with major MedTech firms drive a 48% Q3 net sales increase and improved EBITDA. Advanced infection prevention technology shows 70% risk reduction and supports expansion across multiple therapeutic areas. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab